Next Article in Journal
Effect of the Addition of the Fifth Amino Acid to [GADV]-Protein on the Three-Dimensional Structure
Previous Article in Journal
Trace Element Uptake by Willows Used for the Phytoremediation of Biosolids
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Life
Volume 13
Issue 1
10.3390/life13010245
life-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Evaluation of Blood Levels of Omentin-1 and Orexin-A in Adults with Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis

by
Iman Mohammadi
1,
Masoud Sadeghi
2,
Golnaz Tajmiri
3,
Annette Beatrix Brühl
4,
Laleh Sadeghi Bahmani
5 and
Serge Brand
4,6,7,8,9,10,*
1
Department of Oral and Maxillofacial Surgery, Dental Implants Research Center, Dental Research Institute, School of Dentistry, Isfahan University of Medical Sciences, Isfahan 8174673461, Iran
2
Department of Biology, Science and Research Branch, Islamic Azad University, Tehran 1477893855, Iran
3
Dental Implants Research Center, Dental Research Institute, School of Dentistry, Isfahan University of Medical Sciences, Isfahan 8174673461, Iran
4
Center for Affective, Stress and Sleep Disorders (ZASS), Psychiatric University Hospital Basel, 4002 Basel, Switzerland
5
Department of Education and Psychology, Shahid Ashrafi Esfahani University, Ishafan 8179949999, Iran
6
Sleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah 6715847141, Iran
7
Department of Sport, Exercise and Health, Division of Sport Science and Psychosocial Health, University of Basel, 4052 Basel, Switzerland
8
Substance Abuse Prevention Research Center, Kermanshah University of Medical Sciences, Kermanshah 67146, Iran
9
School of Medicine, Tehran University of Medical Sciences, Tehran 25529, Iran
10
Center for Disaster Psychiatry and Disaster Psychology, Psychiatric University Hospital Basel, 4002 Basel, Switzerland
*
Author to whom correspondence should be addressed.
Life 2023, 13(1), 245; https://doi.org/10.3390/life13010245
Submission received: 27 November 2022 / Revised: 29 December 2022 / Accepted: 10 January 2023 / Published: 16 January 2023
(This article belongs to the Section Medical Research)
Browse Figures
Review Reports Versions Notes

Abstract

:
Background and objective: Obstructive sleep apnea (OSA) can be related to changes in the levels of adipokines and neuropeptides, which in turn may affect the energy balance components of neuronal cells. Herein, a systematic review and meta-analysis checked the changes in serum/plasma levels of omentin-1 (OM-1: an adipokine) and orexin-A (OXA: a neuropeptide) in adults (age > 18 years old) with OSA (aOSA) compared to controls. Materials and methods: Four databases (Cochrane Library, PubMed, Web of Science, and Scopus) were systematically searched until 14 November 2022, without any restrictions. The Joanna Briggs Institute (JBI) critical appraisal checklist adapted for case–control studies was used to assess the quality of the papers. The effect sizes were extracted using the Review Manager 5.3 software for the blood levels of OM-1 and OXA in aOSA compared with controls. Results: Thirteen articles, with six studies for OM-1 levels and eight for OXA levels, were included. The pooled standardized mean differences were −0.85 (95% confidence interval (CI): −2.19, 0.48; p = 0.21; I2 = 98%) and −0.20 (95%CI: −1.16, 0.76; p = 0.68; I2 = 96%) for OM-1 and OXA levels, respectively. Among the studies reporting OM-1, five were high and one was moderate quality. Among the studies reporting OXA, six were moderate, one was high, and one was low quality. Based on the trial sequential analysis, more participants are needed to confirm the pooled results of the analyses of blood levels of OM-1 and OXA. In addition, the radial plot showed outliers as significant factors for high heterogeneity. Conclusions: The main findings indicated a lack of association between the blood levels of OM-1 and OXA and OSA risk. Therefore, OM-1 and OXA did not appear to be suitable biomarkers for the diagnosis and development of OSA.

1. Introduction

Obstructive sleep apnea (OSA) is a status determined by repeated episodes of partial or complete airway obstruction during sleep [1,2], which usually remains undiagnosed and untreated [3]. A systematic review in 2017 reported that the overall prevalence of any OSA ranged from 9% to 38% in the general adult population, from 13% to 33% and 6% to 19% in females and males, respectively, while the overall prevalence increases in older adults [4]. The global prevalence of moderate to severe OSA is approximately 20% [5]. Clinically, the apnea-hypopnea index (AHI) provides well-established and useful cutoff-values which can be applied to diagnose both the OSA severity and to assess the effects of interventions [6,7]. A diagnosis using polysomnography (PSG: the gold standard test for diagnosing OSA) [8,9] with an AHI ≥ 5 is considered indicative of OSA among adults [8,10,11].
Several factors including environmental and genetic factors, and even internal conditions (hormones, cytokines, and other biomarkers), might lead to the emergence and maintenance of OSA. Smoking [12] and alcohol consumption [13], and alterations in the blood levels of intercellular adhesion molecule-1 [14], monocyte chemoattractant protein-1 [15], adiponectin [16], C-reactive protein [17], cortisol [18], interleukin-6 [19], tumor necrosis factor-alpha [20], astrocytic protein (S100B) [21], neuron-specific enolase [21], and polymorphisms [22,23,24] were observed among adults with OSA, compared to healthy controls.
Furthermore, OSA is linked to other diseases such as diabetes, hypertension, cardiovascular diseases, congestive heart failure, and stroke [25,26]; therefore, OSA can be seen as a risk factor for other diseases. As such, the evaluation and treatment of OSA should focus on the recognition of patients at risk of OSA [27]. Obesity is the highest risk factor for OSA and it is estimated that 58% of moderate-to-severe OSA development can be attributed to obesity [28]. Continuous positive airway pressure is still the main treatment for patients with OSA because of its effect on the symptoms and on quality of life [29,30].
Obesity—an energy balance disorder—is associated with a positive energy balance, understood as an imbalance between higher energy storage and energy consumption [31,32]. Orexin-A (OXA or hypocretin-1) is a neuropeptide that plays a role in appetite [33], sleep, and arousal arrangement [34]. OXA can play a role in obesity [35]. The adipocytokine omentin-1 (OM-1 or intelectin-1) is expressed in visceral adipose tissue and is related to the inflammatory response [36]. The reduced serum levels of OM-1 are linked with obesity and type 2 diabetes mellitus (T2DM) [37]. OM-1 may be necessary for holding the energy balance in a time of insulin resistance pathogenesis and T2DM [38]. The energy balance components can be affected by OSA and thus allow clinicians to more effectively guide overall therapeutic approaches to optimize weight loss and promote cardiovascular health in individuals with OSA [39].
A number of studies have evaluated the association between blood OM-1 [40,41] and OXA [42,43] levels in adults with OSA (aOSA) compared to controls, but there were different and, above all, contrasting results. In addition, based on our knowledge, there was no previous meta-analysis in the English-language literature. Therefore, we designed a systematic review and meta-analysis evaluating the association between blood OM-1 and OXA levels in aOSA versus controls.

2. Materials and Methods

To design the present meta-analysis, the PRISMA-P items [44] were followed. The PECO question [45,46] was: Are blood OM-1 and OXA levels different in aOSA in comparison with controls? (P: human adults with/without OSA, E: OSA disorder, C: aOSA in comparison with controls; and O: the plasma/serum levels of OM-1 or OXA).

2.1. Search Strategy

The databases of Cochrane Library, PubMed, Web of Science, and Scopus were comprehensively searched by one author (M.S.) until 14 November 2022, without any restrictions. The search terms were: (“obstructive sleep apnea” or “OSA” or “sleep apnea” or “obstructive sleep apnea-hypopnea syndrome” or “OSAHS” or “obstructive sleep apnea syndrome” or “OSAS”) AND (“hypocretin” or “orexin-A” or “OXA” or “omentin-1” or “OM-1” or “intelectin-1”). The citations of any article linked to the subject and the databases of “Google Scholar”, “Elsevier publishers”, and “BMJ publishers” were checked so that no study was missed. Two authors working independently (M.S. and I.M.) were responsible for removing irrelevant articles and excluding articles with reasons. There was no disagreement.

2.2. Eligibility Criteria

Inclusion criteria: (1) Studies involving both groups of adults (aOSA and controls); (2) Both groups had no treatment during sampling; (3) In both groups, participants were 18 years old or older, with no restrictions on BMI values; (4) Studies reporting plasma/serum hypocretin, orexin-A, omentin-1, or interlectin-1 levels in OSA and controls; (5) PSG was used for diagnosing OSA; (6) OSA in adults was defined as an AHI ≥ 5 events/h; (7) Participants included in the studies did not report other systemic diseases (cardiovascular diseases; diabetes mellitus; infectious diseases; any malignancy; heart, renal, and hepatic failures; lung diseases; and other sleep disorders); (8) Controls had no OSA or systemic diseases (see the previous criterion); (9) Venous blood was taken in a fasting state in the morning to measure OM-1 and OXA levels. Exclusion criteria: (1) Meta-analyses, letters to the editor, book chapters, conference papers, reviews, and commentaries; (2) Studies with a lack of complete data; (3) Studies with no control group.

2.3. Data Collection

The data were extracted for any study by one author (I.M.), including the country and ethnicity of participants, the first author, the publication year, OM-1 and OXA sampling, the sample size of both groups (aOSA and controls), mean BMI, mean age and mean AHI of two groups, quality or quality score, and mean serum/plasma levels of OM-1 and OXA in two groups. Another author (G.T) re-checked the process of extraction; in case of disagreements between the two authors’ decisions, a discussion between all three authors resolved the issue.

2.4. Quality Assessment

Two authors (M.S. and S.B.) independently evaluated the quality based on the Joanna Briggs Institute (JBI) critical appraisal checklist adapted for case–control studies including ten questions or ten scores. Low-quality studies had a score of 1–4; moderate- quality studies, 5–7; and high-quality studies: 8–10 [47] (See Supplementary Materials).

2.5. Statistical Analyses

The statistical analyses were performed by one author (M.S.). The standardized mean difference (SMD) and 95% confidence interval (CI)) of blood levels of OM-1 and OXA amongst aOSA and controls were extracted using the Review Manager 5.3 (RevMan 5.3; the Cochrane Collaboration, the Nordic Cochrane Centre, Copenhagen, Denmark) software. A significant value was considered when the p-value (2-sided) was less than 0.05. The significant heterogeneity was considered while Pheterogeneity < 0.1 (I2 > 50%) and in the state, the analysis was performed in a random-effect model [48]; otherwise, it was performed in a fixed-effect model [49]. In addition, the radial plot result was reported to confirm or reject the heterogeneity due to outliers among the studies.
The subgroup and mixed-effect meta-regression analyses were based on several variables, and the stability of initial pooled SMDs was assessed by both “one-study-removed” and “cumulative” analyses as sensitivity analyses.
Begg’s and Egger’s tests were applied to test the potential publication bias [50] and to report the degree of asymmetry [51], respectively; the data for publication bias and sensitivity analyses were extracted using the Comprehensive Meta-Analysis version 2.0 (CMA 2.0; Biostat Inc., Englewood, NJ, USA) software, with a p-value (2-sided) less than 0.10 recommending the existence of the significant publication bias.
To report the potential random error (false-positive and -negative results) in the meta-analysis [52], trial sequential analysis (TSA) was accomplished using TSA software (version 0.9.5.10 beta) (Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen, Denmark) [53]. The futility threshold could show a no-impact result before attaining the information size. To calculate the required information size (RIS), an α-risk of 5%, β-risk of 20%, and two-sided border type were used to extract the mean difference and variance according to the empirical assumptions created by the TSA software automatically. If the Z-curve reached the RIS line, enough participants were included in the studies, the conclusions were reliable or crossed the boundaries, and the results could be strong. On the other hand, the volume of information was not large enough and more evidence was needed.
Some studies reported the effect sizes based on median and 25th–75th percentiles [54] or median (min-max) [55], and in the state, we changed them to the mean (standard deviation) based on just entering the format into the software.
All authors checked the last version of the article and the disagreement was resolved by a discussion between them.

3. Results

3.1. Study Selection

To search the databases, 716 records were extracted, and after removing duplicates and irrelevant records, 26 full-text articles were assessed using the eligibility criteria. Then, 13 full-text articles were removed for different reasons (Figure 1). Finally, 13 articles including 6 studies reporting blood OM-1 levels and 9 reporting OXA levels entered the meta-analysis.

3.2. Characteristics of Studies

Table 1 reports the data for the variables of fourteen studies from the thirteen articles [40,41,42,43,56,57,58,59,60,61,62,63,64] included in the meta-analysis. With regard to the studies reporting OM-1 levels, four were reported among Caucasians and two among Asians, and for the studies reporting OXA levels, three were among Caucasians and five among Asians. For OM-1, three studies reported plasma and three reported serum levels; however, for OXA, seven reported plasma levels and one reported the serum level.

3.3. Quality Assessment

Table 2 reports the JBI critical appraisal checklist for both blood OM-1 and OXA levels in case–control studies. Among the studies reporting OM-1, five were high and one was moderate quality. Among the studies reporting OXA, six were moderate, one was high, and one was low quality. The questions for the JBI critical appraisal checklist are located in Supplementary Materials.

3.4. Meta-Analysis for OM-1 Levels

Figure 2 shows the random-effect analysis of blood OM-1 levels in aOSA compared to controls. The pooled result showed a lack of association between the blood levels of OM-1 and OSA risk (SMD = −0.85; 95%CI: −2.19, 0.48; p = 0.21; I2 = 98%).

3.5. Meta-Analysis for OXA Levels

Figure 3 illustrates the random-effect analysis of blood OXA levels in aOSA compared to controls. The pooled result showed a lack of association between the blood levels of OXA and OSA risk (SMD = −0.20; 95%CI: −1.16, 0.76; p = 0.68; I2 = 96%).

3.6. Subgroup Analysis for OM-1 Levels

Table 3 reports the subgroup analysis based on the variables for finding confounding factors in the pooled analysis of the serum/plasma levels of OM-1 in aOSA compared with controls. The results reported that the mean AHI of aOSA and quality were two confounding factors in the pooled SMD.

3.7. Subgroup Analysis for OXA Levels

Table 4 reports the subgroup analysis based on the variables for finding confounding factors in the pooled analysis of the serum/plasma levels of OXA in aOSA compared to controls. The results reported that the mean BMI in controls, the mean age of aOSA, and the quality were three confounding factors in the pooled SMD.

3.8. Meta-Regression Analysis

As Table 5 shows, among the eight variables checked in the meta-regression analysis for both OM-1 and OXA levels, just sample size was an effective factor for the pooled SMD of blood OM-1 levels (p = 0.00445). With an increasing sample size, OM-1 levels were significantly reduced.

3.9. Radial Plot

Figure 4 shows radial plots for OM-1 and OXA levels in aOSA compared to controls. The results confirmed a significant high heterogeneity due to outliers among the studies reporting OM-1 (Cochran’s Q = 46.01; p < 0.01) and OXA (Cochran’s Q = 299.08; p < 0.01) levels.

3.10. Sensitivity Analysis

The sensitivity analyses (one-study-removed and cumulative analyses) showed the stability of the pooled results for both OM-1 and OXA levels in aOSA compared to controls. The plots for the sensitivity analyses are located in the Supplementary Materials.

3.11. Trial Sequential Analysis (TSA)

Figure 5 shows the TSAs of the blood levels of OM-1 and OXA in aOSA compared to controls. The TSA of six studies for blood OM-1 levels shows the line of the cumulative Z-curve crossed the line of the trial sequential monitoring boundary for benefit, but not the line of RIS (heterogeneity (D2) = 98%). The result was robust, before reaching the information size needed to obtain reliable evidence adjusted for random error risk and suggesting further studies. The TSA of eight studies for blood OXA levels shows the line of the cumulative Z-curve did not cross any line (D2 = 99%). Therefore, it indicated an absence of evidence if the information size is not reached and that further studies are needed.

3.12. Publication Bias

Figure 6 shows the funnel plots of serum/plasma OM-1 and OXA levels with the results of the trim-fill method in aOSA compared to controls. The p-values of Egger’s/ Begg’s tests for OM-1 and OXA levels were 0.516/0.851 and 0.161/0.458, respectively. For serum/plasma OM-1 levels and having one imputed study, under the fixed-effects model, the point estimate and pseudo 95% CI for the combined studies was −1.214 (−1.389, −1.039); using the trim-fill method, the imputed point estimate was −1.292 (−1.463, −1.120). In addition, under the random-effects model, the point estimate and 95% CI for the combined studies was −0.837 (−2.197, 0.523); using the trim-fill method, the imputed point estimate was −1.190 (−2.764, 0.085). Therefore, the overall effect sizes on blood OM-1 levels reported in the forest plot appeared valid; with a trivial publication bias effect based the on fixed-effects and random-effects models, because the observed estimates were similar to the adjusted estimates.
For serum/plasma OXA levels and without any imputed study, under the fixed-effects model, the point estimate and pseudo 95% CI for the combined studies was 0.307 (0.126, 0.487); using the trim-fill method, the imputed point estimate was 0.307 (0.126, 0.487). In addition, under the random-effects model, the point estimate and 95% CI for the combined studies was −0.211 (−1.189, 0.766); using the trim-fill method, the imputed point estimate was −0.211 (−1.189, 0.766). Therefore, the overall effect sizes on blood OXA levels reported in the forest plot appeared valid, with a trivial publication bias effect based on the fixed-effects and random-effects models, because the observed estimates were similar to the adjusted estimates.

4. Discussion

Despite a low number of cases and high heterogeneity, the results of the meta-analysis represented a lack of association between the blood levels of OM-1 and OXA and OSA risk. Sample size, mean AHI of aOSA, and quality were confounding factors for OM-1 levels, whereas, mean BMI in controls, mean age of aOSA, and quality were confounding factors for OXA levels.
OSA must be investigated as a multifactorial disease in which multiple polymorphisms, environmental influences, and developmental factors are closely related to it [65]; OSA is also strongly correlated with obesity [66]. The main mechanisms of OSA are hypoxia and oxidative stress; however, several studies have shown that inflammation also plays an important role in the occurrence and progression of OSA [67,68,69]. OSA appears to affect parameters involved in the regulation of energy balance, including food consumption, physical activity, energy metabolism, and the hormonal regulation of hunger/satiety [70,71].
There is a relationship between OM-1 level, body composition, and physical activity in elderly women [72]. Aging, physical activity, and body weight are several significant factors affecting OM-1 concentration. However, it is not clear what factors can be used as predictors of the impact of the circulating OM-1 concentration [73,74]. OXA stimulates both nutrition and energy intake, and OXA’s increase in energy intake is mainly due to increased spontaneous physical activity, and this effect on energy intake is stronger than the effect on nutrition [75]. OXA has been demonstrated to cause obesity and its related diseases [35].
Three studies [41,60,62] reported that the OM-1 levels were significantly lower in aOSA than those in controls. The decreased levels of OM-1 are related to insulin resistance T2DM, coronary artery disease, and arterial stiffness, or on the other hand, associated inversely with metabolic syndrome [76,77,78,79,80,81]. In contrast, two studies [40,64], in line with the present meta-analysis, reported there was no association between OM-1 levels and OSA risk. These different results of the studies can be due to the differences in sample size, BMI status, age, and quality of the studies.
Three studies [42,59,63] showed a reduced significant level of OXA in aOSA compared to controls. In contrast, three articles [43,57,58] reported an elevated significant level of OXA in aOSA compared to controls. Low levels of OXA may prevent arousal during sleep or may be the result of sleepiness from repeated arousals caused by a mechanism independent of OXA [42], and also obesity in individuals with OSA may be induced by decreased orexin neuron activity or levels of OXA [82]. Higher levels of OXA were related to high breakfast energy intake [83]. In addition, elevated orexin transmission, reflected as elevated plasma levels of OXA, may impact the arousal response in individuals with OSA [57]. The results of the present meta-analysis are in line with another study [61] which found a lack of association between OXA levels in aOSA versus controls. These different results of the studies can be due to the differences in AHI status and the quality of the studies.
The present results should be counterbalanced by the following limitations: (1) A low number of cases in most studies; (2) A low number of studies in each analysis; (3) A high heterogeneity across or among the studies; (4) Some studies were outliers; (5) A lack of high quality in most studies. In contrast, there were two strengths: (1) Stability of the pooled results; (2) A lack of publication bias.

5. Conclusions

The main results indicated a lack of association between the blood levels of OM-1 and OXA and OSA risk. Therefore, OM-1 and OXA did not appear to be suitable biomarkers for the diagnosis and development of OSA. Although we used eligibility criteria, our results must be interpreted with precaution, because the levels of the two biomarkers may be impacted by several factors (age, BMI, AHI, sample size, etc.). Finally, the sample sizes in most studies were relatively small, and, therefore, larger and multi-center studies should be analyzed to clarify the relationship between the blood levels of these biomarkers and OSA development.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/life13010245/s1, Figure S1: One-study-remove analysis of blood omentin-1 levels in adults with OSA compared to control; Figure S2: Cumulative analysis of blood omentin-1 levels in adults with OSA compared to controls; Figure S3: One-study-remove analysis of blood orexin-A levels in adults with OSA compared to controls; Figure S4: Cumulative analysis of blood orexin-A levels in adults with OSA compared to controls; Table S1: The Joanna Briggs Institute (JBI) Critical Appraisal Checklist for case-control studies.

Author Contributions

Conceptualization, I.M.; methodology, M.S.; software, M.S.; validation, M.S. and S.B.; formal analysis, M.S.; investigation, I.M.; resources, G.T.; data curation, M.S.; writing—original draft preparation, S.B.; writing—review and editing, M.S., L.S.B. and A.B.B. visualization, M.S.; supervision, I.M.; project administration, I.M.; funding acquisition, I.M. and S.B. All authors have read and agreed to the published version of the manuscript.

Funding

University and University Hospital of Basel (Basel, Switzerland) funded the Article Processing Charge (APC) of this manuscript.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Pretto, J.J.; Gyulay, S.G.; Hensley, M.J. Trends in anthropometry and severity of sleep-disordered breathing over two decades of diagnostic sleep studies in an Australian adult sleep laboratory. Med. J. Aust. 2010, 193, 213–216. [Google Scholar] [CrossRef] [PubMed]
  2. Park, J.G.; Ramar, K.; Olson, E.J. Updates on definition, consequences, and management of obstructive sleep apnea. Mayo Clin. Proc. 2011, 86, 549–554, quiz 554–555. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Kuczyński, W.; Mokros, Ł.; Stolarz, A.; Białasiewicz, P. The utility of STOP-BANG questionnaire in the sleep-lab setting. Sci. Rep. 2019, 9, 6676. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Senaratna, C.V.; Perret, J.L.; Lodge, C.J.; Lowe, A.J.; Campbell, B.E.; Matheson, M.C.; Hamilton, G.S.; Dharmage, S.C. Prevalence of obstructive sleep apnea in the general population: A systematic review. Sleep Med. Rev. 2017, 34, 70–81. [Google Scholar] [CrossRef] [PubMed]
  5. Lechat, B.; Naik, G.; Reynolds, A.; Aishah, A.; Scott, H.; Loffler, K.A.; Vakulin, A.; Escourrou, P.; McEvoy, R.D.; Adams, R.J. Multinight prevalence, variability, and diagnostic misclassification of obstructive sleep apnea. Am. J. Respir. Crit. Care Med. 2022, 205, 563–569. [Google Scholar] [CrossRef]
  6. Cielo, C.M.; Tapia, I.E. Diving deeper: Rethinking AHI as the primary measure of OSA severity. J. Clin. Sleep Med. 2019, 15, 1075–1076. [Google Scholar] [CrossRef]
  7. Quan, S.; Gillin, J.C.; Littner, M.; Shepard, J. Sleep-related breathing disorders in adults: Recommendations for syndrome definition and measurement techniques in clinical research. editorials. Sleep 1999, 22, 662–689. [Google Scholar] [CrossRef] [Green Version]
  8. Goyal, M.; Johnson, J. Obstructive sleep apnea diagnosis and management. Mo. Med. 2017, 114, 120. [Google Scholar]
  9. Epstein, L.J.; Kristo, D.; Strollo, P.J., Jr.; Friedman, N.; Malhotra, A.; Patil, S.P.; Ramar, K.; Rogers, R.; Schwab, R.J.; Weaver, E.M.; et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J. Clin. Sleep Med. 2009, 5, 263–276. [Google Scholar]
  10. Franklin, K.A.; Lindberg, E. Obstructive sleep apnea is a common disorder in the population—A review on the epidemiology of sleep apnea. J. Thorac. Dis. 2015, 7, 1311. [Google Scholar]
  11. Schwartz, M.; Acosta, L.; Hung, Y.-L.; Padilla, M.; Enciso, R. Effects of CPAP and mandibular advancement device treatment in obstructive sleep apnea patients: A systematic review and meta-analysis. Sleep Breath. 2018, 22, 555–568. [Google Scholar] [CrossRef]
  12. Bielicki, P.; Trojnar, A.; Sobieraj, P. The impact of smoking status on obstructive sleep apnea (OSA) severity. Eur. Respir. J. 2018, 52, PA4356. [Google Scholar]
  13. Simou, E.; Britton, J.; Leonardi-Bee, J. Alcohol and the risk of sleep apnoea: A systematic review and meta-analysis. Sleep Med. 2018, 42, 38–46. [Google Scholar] [CrossRef]
  14. Imani, M.M.; Sadeghi, M.; Gholamipour, M.A.; Brühl, A.B.; Sadeghi-Bahmani, D.; Brand, S. Evaluation of Blood Intercellular Adhesion Molecule-1 (ICAM-1) Level in Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis. Medicina 2022, 58, 1499. [Google Scholar] [CrossRef]
  15. Imani, M.M.; Sadeghi, M.; Mohammadi, M.; Brühl, A.B.; Sadeghi-Bahmani, D.; Brand, S. Association of Blood MCP-1 Levels with Risk of Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis. Medicina 2022, 58, 1266. [Google Scholar] [CrossRef]
  16. Najafi, A.; Mohammadi, I.; Sadeghi, M.; Brühl, A.B.; Sadeghi-Bahmani, D.; Brand, S. Evaluation of Plasma/Serum Adiponectin (an Anti-Inflammatory Factor) Levels in Adult Patients with Obstructive Sleep Apnea Syndrome: A Systematic Review and Meta-Analysis. Life 2022, 12, 738. [Google Scholar] [CrossRef]
  17. Imani, M.M.; Sadeghi, M.; Farokhzadeh, F.; Khazaie, H.; Brand, S.; Dürsteler, K.M.; Brühl, A.; Sadeghi-Bahmani, D. Evaluation of Blood Levels of C-Reactive Protein Marker in Obstructive Sleep Apnea: A Systematic Review, Meta-Analysis and Meta-Regression. Life 2021, 11, 362. [Google Scholar] [CrossRef]
  18. Imani, M.M.; Sadeghi, M.; Khazaie, H.; Sanjabi, A.; Brand, S.; Brühl, A.; Sadeghi Bahmani, D. Associations Between Morning Salivary and Blood Cortisol Concentrations in Individuals With Obstructive Sleep Apnea Syndrome: A Meta-Analysis. Front. Endocrinol. 2020, 11, 568823. [Google Scholar] [CrossRef]
  19. Imani, M.M.; Sadeghi, M.; Khazaie, H.; Emami, M.; Sadeghi Bahmani, D.; Brand, S. Evaluation of Serum and Plasma Interleukin-6 Levels in Obstructive Sleep Apnea Syndrome: A Meta-Analysis and Meta-Regression. Front. Immunol. 2020, 11, 1343. [Google Scholar] [CrossRef]
  20. Imani, M.M.; Sadeghi, M.; Khazaie, H.; Emami, M.; Sadeghi Bahmani, D.; Brand, S. Serum and Plasma Tumor Necrosis Factor Alpha Levels in Individuals with Obstructive Sleep Apnea Syndrome: A Meta-Analysis and Meta-Regression. Life 2020, 10, 87. [Google Scholar] [CrossRef]
  21. Rezaei, F.; Abbasi, H.; Sadeghi, M.; Imani, M.M. The effect of obstructive sleep apnea syndrome on serum S100B and NSE levels: A systematic review and meta-analysis of observational studies. BMC Pulm. Med. 2020, 20, 31. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Bhatt, S.P.; Guleria, R. Association of IRS1 (Gly972Arg) and IRS2 (Gly1057Asp) genes polymorphisms with OSA and NAFLD in Asian Indians. PLoS ONE 2021, 16, e0245408. [Google Scholar] [CrossRef] [PubMed]
  23. Kerget, B.; Kerget, F.; Kahraman, Ç.Y.; Aksakal, A.; Araz, Ö. The relationship between NLRP3 rs10159239 and Vaspin rs2236242 gene variants and obstructive sleep apnea. Upsala J. Med. Sci. 2021, 126, e7603. [Google Scholar] [CrossRef]
  24. Behboudi, A.; Thelander, T.; Yazici, D.; Celik, Y.; Yucel-Lindberg, T.; Thunström, E.; Peker, Y. Association of TNF-α (-308G/A) Gene Polymorphism with Circulating TNF-α Levels and Excessive Daytime Sleepiness in Adults with Coronary Artery Disease and Concomitant Obstructive Sleep Apnea. J. Clin. Med. 2021, 10, 3413. [Google Scholar] [CrossRef] [PubMed]
  25. Netzer, N.C.; Stoohs, R.A.; Netzer, C.M.; Clark, K.; Strohl, K.P. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann. Intern. Med. 1999, 131, 485–491. [Google Scholar] [CrossRef]
  26. Shamsuzzaman, A.S.; Gersh, B.J.; Somers, V.K. Obstructive sleep apnea: Implications for cardiac and vascular disease. JAMA 2003, 290, 1906–1914. [Google Scholar] [CrossRef]
  27. Gunta, S.P.; Jakulla, R.S.; Ubaid, A.; Mohamed, K.; Bhat, A.; López-Candales, A.; Norgard, N. Obstructive Sleep Apnea and Cardiovascular Diseases: Sad Realities and Untold Truths regarding Care of Patients in 2022. Cardiovasc. Ther. 2022, 2022, 6006127. [Google Scholar] [CrossRef]
  28. Young, T.; Peppard, P.E.; Taheri, S. Excess weight and sleep-disordered breathing. J. Appl. Physiol. 2005, 99, 1592–1599. [Google Scholar] [CrossRef]
  29. Patel, S.R.; White, D.P.; Malhotra, A.; Stanchina, M.L.; Ayas, N.T. Continuous positive airway pressure therapy for treating gess in a diverse population with obstructive sleep apnea: Results of a meta-analysis. Arch. Intern. Med. 2003, 163, 565–571. [Google Scholar] [CrossRef] [Green Version]
  30. Patil, S.P.; Ayappa, I.A.; Caples, S.M.; Kimoff, R.J.; Patel, S.R.; Harrod, C.G. Treatment of adult obstructive sleep apnea with positive airway pressure: An American Academy of Sleep Medicine clinical practice guideline. J. Clin. Sleep Med. 2019, 15, 335–343. [Google Scholar] [CrossRef] [Green Version]
  31. Jaacks, L.M.; Vandevijvere, S.; Pan, A.; McGowan, C.J.; Wallace, C.; Imamura, F.; Mozaffarian, D.; Swinburn, B.; Ezzati, M. The obesity transition: Stages of the global epidemic. Lancet Diabetes Endocrinol. 2019, 7, 231–240. [Google Scholar] [CrossRef]
  32. Bi, X.; Loo, Y.T.; Henry, C.J. Does circulating leptin play a role in energy expenditure? Nutrition 2019, 60, 6–10. [Google Scholar] [CrossRef]
  33. Sartin, J.; Dyer, C.; Matteri, R.; Buxton, D.; Buonomo, F.; Shores, M.; Baker, J.; Osborne, J.; Braden, T.; Steele, B. Effect of intracerebroventricular orexin-B on food intake in sheep. J. Anim. Sci. 2001, 79, 1573–1577. [Google Scholar] [CrossRef]
  34. Taheri, S.; Ward, H.; Ghatei, M.; Bloom, S. Role of orexins in sleep and arousal mechanisms. Lancet 2000, 355, 847. [Google Scholar] [CrossRef]
  35. Imperatore, R.; Palomba, L.; Cristino, L. Role of orexin-A in hypertension and obesity. Curr. Hypertens. Rep. 2017, 19, 34. [Google Scholar] [CrossRef]
  36. Yin, J.; Hou, P.; Wu, Z.; Nie, Y. Decreased levels of serum omentin-1 in patients with inflammatory bowel disease. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2015, 21, 118. [Google Scholar]
  37. El-Mesallamy, H.; El-Derany, M.; Hamdy, N. Serum omentin-1 and chemerin levels are interrelated in patients with Type 2 diabetes mellitus with or without ischaemic heart disease. Diabet. Med. 2011, 28, 1194–1200. [Google Scholar] [CrossRef]
  38. Elsaid, N.H.; Sadik, N.A.; Ahmed, N.R.; Fayez, S.E.; Mohammed, N.A.E.-G. Serum omentin-1 levels in type 2 diabetic obese women in relation to glycemic control, insulin resistance and metabolic parameters. J. Clin. Transl. Endocrinol. 2018, 13, 14–19. [Google Scholar] [CrossRef]
  39. Shechter, A. Obstructive sleep apnea and energy balance regulation: A systematic review. Sleep Med. Rev. 2017, 34, 59–69. [Google Scholar] [CrossRef] [Green Version]
  40. Kurt, O.K.; Tosun, M.; Alcelik, A.; Yilmaz, B.; Talay, F. Serum omentin levels in patients with obstructive sleep apnea. Sleep Breath. 2014, 18, 391–395. [Google Scholar] [CrossRef]
  41. Wang, Q.; Feng, X.; Zhou, C.; Li, P.; Kang, J. Decreased levels of serum omentin-1 in patients with obstructive sleep apnoea syndrome. Ann. Clin. Biochem. 2013, 50, 230–235. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Busquets, X.; Barbé, F.; Barceló, A.; de la Peña, M.; Sigritz, N.; Mayoralas, L.R.; Ladaria, A.; Agustí, A. Decreased plasma levels of orexin-A in sleep apnea. Respiration 2004, 71, 575–579. [Google Scholar] [CrossRef] [PubMed]
  43. Liao, X.; Yu, Q. The changes and implications of plasma orexin-A levels in patients with obstructive sleep apnea-hypopnea syndrome. Zhonghua Jie He He Hu Xi Za Zhi/Zhonghua Jiehe He Huxi Zazhi/Chin. J. Tuberc. Respir. Dis. 2005, 28, 368–371. [Google Scholar]
  44. Moher, D.; Shamseer, L.; Clarke, M.; Ghersi, D.; Liberati, A.; Petticrew, M.; Shekelle, P.; Stewart, L.A. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst. Rev. 2015, 4, 1. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Morgan, R.L.; Thayer, K.A.; Bero, L.; Bruce, N.; Falck-Ytter, Y.; Ghersi, D.; Guyatt, G.; Hooijmans, C.; Langendam, M.; Mandrioli, D. GRADE: Assessing the quality of evidence in environmental and occupational health. Environ. Int. 2016, 92, 611–616. [Google Scholar] [CrossRef] [Green Version]
  46. Morgan, R.L.; Thayer, K.A.; Santesso, N.; Holloway, A.C.; Blain, R.; Eftim, S.E.; Goldstone, A.E.; Ross, P.; Guyatt, G.; Schünemann, H.J. Evaluation of the risk of bias in non-randomized studies of interventions (ROBINS-I) and the ‘target experiment’concept in studies of exposures: Rationale and preliminary instrument development. Environ. Int. 2018, 120, 382–387. [Google Scholar] [CrossRef]
  47. Institute, J. The Joanna Briggs Institute Critical Appraisal Tools for Use in JBI Systematic Reviews Checklist for Analytical Clinical Trial Studies. 2017. Available online: https://jbi.global/critical-appraisal-tools (accessed on 27 November 2022).
  48. DerSimonian, R.; Laird, N. Meta-analysis in clinical trials revisited. Contemp. Clin. Trials 2015, 45, 139–145. [Google Scholar] [CrossRef] [Green Version]
  49. Mantel, N.; Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 1959, 22, 719–748. [Google Scholar]
  50. Begg, C.B.; Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50, 1088–1101. [Google Scholar] [CrossRef]
  51. Egger, M.; Smith, G.D.; Schneider, M.; Minder, C. Bias in meta-analysis detected by a simple, graphical test. Bmj 1997, 315, 629–634. [Google Scholar] [CrossRef] [Green Version]
  52. Imberger, G.; Thorlund, K.; Gluud, C.; Wetterslev, J. False-positive findings in Cochrane meta-analyses with and without application of trial sequential analysis: An empirical review. BMJ Open 2016, 6, e011890. [Google Scholar] [CrossRef]
  53. Wetterslev, J.; Jakobsen, J.C.; Gluud, C. Trial sequential analysis in systematic reviews with meta-analysis. BMC Med. Res. Methodol. 2017, 17, 39. [Google Scholar] [CrossRef] [Green Version]
  54. Wan, X.; Wang, W.; Liu, J.; Tong, T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med. Res. Methodol. 2014, 14, 135. [Google Scholar] [CrossRef] [Green Version]
  55. Hozo, S.P.; Djulbegovic, B.; Hozo, I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med. Res. Methodol. 2005, 5, 13. [Google Scholar] [CrossRef] [Green Version]
  56. Bİçer, Ü.; Kutlu, R.; Yosunkaya, S.; Kilinç, İ. Evaluation of Plasma Ghrelin, Omentin–1 Levels and Insulin Resistance in Patients With Obstructive Sleep Apnea Syndrome. Konuralp Med. J. 2021, 13, 114–121. [Google Scholar] [CrossRef]
  57. Igarashi, N.; Tatsumi, K.; Nakamura, A.; Sakao, S.; Takiguchi, Y.; Nishikawa, T.; Kuriyama, T. Plasma orexin-A levels in obstructive sleep apnea-hypopnea syndrome. Chest 2003, 124, 1381–1385. [Google Scholar] [CrossRef] [Green Version]
  58. Öztürk, Ö.; Cebeci, D.; Şahin, U.; Tülüceoğlu, E.E.; Calapoğlu, N.Ş.; Gonca, T.; Calapoğlu, M. Circulating levels of ghrelin, galanin, and orexin-A orexigenic neuropeptides in obstructive sleep apnea syndrome. Sleep Breath. 2022, 26, 1209–1218. [Google Scholar] [CrossRef]
  59. Strueva, N.; Poluektov, M.; Melnichenko, G.; Savelyeva, L.; Katsya, G.; Goncharov, N. Decreased plasma orexin-A levels in obese patients with and without obstructive sleep apnea. Sleep Med. 2015, 16, S86. [Google Scholar] [CrossRef]
  60. Uygur, F.; Tanrıverdi, H.; Can, M.; Erboy, F.; Altınsoy, B.; Atalay, F.; Ornek, T.; Damar, M.; Kokturk, F.; Tor, M. Association between continuous positive airway pressure and circulating omentin levels in patients with obstructive sleep apnoea. Sleep Breath. 2016, 20, 939–945. [Google Scholar] [CrossRef]
  61. Yao, X.; Yang, H.; Zhang, G.; Tang, Y. Plasma orexin-A level in patients with obstructive apnea-hypopnea syndrome. Lin Chuang Er Bi Yan Hou Ke Za Zhi/J. Clin. Otorhinolaryngol. 2006, 20, 547–549. [Google Scholar]
  62. Zhang, D.-m.; Pang, X.-l.; Huang, R.; Gong, F.-y.; Zhong, X.; Xiao, Y. Adiponectin, omentin, ghrelin, and visfatin levels in obese patients with severe obstructive sleep apnea. BioMed Res. Int. 2018, 2018, 3410135. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  63. Zhu, J.; Zeng, Z.; Xiong, M.; Mo, H.; Jin, M.; Hu, K. Associations between daytime and nighttime plasma orexin A levels and cognitive function in patients with obstructive sleep apnea. Sleep Biol. Rhythm. 2022, 20, 421–429. [Google Scholar] [CrossRef]
  64. Zirlik, S.; Hildner, K.; Targosz, A.; Neurath, M.; Fuchs, F.; Brzozowski, T.; Konturek, P.C. Melatonin and omentin: Influence factors in the obstructive sleep apnoea syndrome. J Physiol Pharm. 2013, 64, 353–360. [Google Scholar]
  65. Casale, M.; Pappacena, M.; Rinaldi, V.; Bressi, F.; Baptista, P.; Salvinelli, F. Obstructive sleep apnea syndrome: From phenotype to genetic basis. Curr. Genom. 2009, 10, 119–126. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Glicksman, A.; Hadjiyannakis, S.; Barrowman, N.; Walker, S.; Hoey, L.; Katz, S.L. Body fat distribution ratios and obstructive sleep apnea severity in youth with obesity. J. Clin. Sleep Med. 2017, 13, 545–550. [Google Scholar] [CrossRef] [Green Version]
  67. Unnikrishnan, D.; Jun, J.; Polotsky, V. Inflammation in sleep apnea: An update. Rev. Endocr. Metab. Disord. 2015, 16, 25–34. [Google Scholar] [CrossRef] [Green Version]
  68. Yilmaz Avci, A.; Avci, S.; Lakadamyali, H.; Can, U. Hypoxia and inflammation indicate significant differences in the severity of obstructive sleep apnea within similar apnea-hypopnea index groups. Sleep Breath. 2017, 21, 703–711. [Google Scholar] [CrossRef]
  69. Vicente, E.; Marin, J.M.; Carrizo, S.J.; Osuna, C.S.; González, R.; Marin-Oto, M.; Forner, M.; Vicente, P.; Cubero, P.; Gil, A.V. Upper airway and systemic inflammation in obstructive sleep apnoea. Eur. Respir. J. 2016, 48, 1108–1117. [Google Scholar] [CrossRef] [Green Version]
  70. St-Onge, M.-P.; Shechter, A. Sleep disturbances, body fat distribution, food intake and/or energy expenditure: Pathophysiological aspects. Horm. Mol. Biol. Clin. Investig. 2014, 17, 29–37. [Google Scholar] [CrossRef]
  71. Shechter, A. Effects of continuous positive airway pressure on energy balance regulation: A systematic review. Eur. Respir. J. 2016, 48, 1640–1657. [Google Scholar] [CrossRef] [Green Version]
  72. Li, S.; Xue, J.; Hong, P. Relationships between serum omentin-1 concentration, body composition and physical activity levels in older women. Medicine 2021, 100, e25020. [Google Scholar] [CrossRef]
  73. Alissa, E.M.; Maisa’a, M.; Alama, N.A.; Ferns, G.A. Role of omentin-1 and C-reactive protein in obese subjects with subclinical inflammation. J. Clin. Transl. Endocrinol. 2016, 3, 7–11. [Google Scholar] [CrossRef] [Green Version]
  74. Wang, D.; Jiang, T.-J.; Liao, L.; Huang, J. Relationships between serum omentin-1 concentration and bone mineral density, and bone biochemical markers in Chinese women. Clin. Chim. Acta 2013, 426, 64–67. [Google Scholar] [CrossRef]
  75. Nixon, J.P.; Kotz, C.M.; Novak, C.M.; Billington, C.J.; Teske, J.A. Neuropeptides controlling energy balance: Orexins and neuromedins. Appet. Control 2012, 209, 77–109. [Google Scholar]
  76. Biscetti, F.; Nardella, E.; Bonadia, N.; Angelini, F.; Pitocco, D.; Santoliquido, A.; Filipponi, M.; Landolfi, R.; Flex, A. Association between plasma omentin-1 levels in type 2 diabetic patients and peripheral artery disease. Cardiovasc. Diabetol. 2019, 18, 74. [Google Scholar] [CrossRef]
  77. Knaus, C. Diagnosis and treatment of obstructive sleep apnea syndrome. Ther. Umschau. Rev. Ther. 2016, 73, 209–212. [Google Scholar] [CrossRef]
  78. Pan, X.; Kaminga, A.C.; Wen, S.W.; Acheampong, K.; Liu, A. Omentin-1 in diabetes mellitus: A systematic review and meta-analysis. PLoS ONE 2019, 14, e0226292. [Google Scholar] [CrossRef] [Green Version]
  79. Svatikova, A.; Wolk, R.; Gami, A.S.; Pohanka, M.; Somers, V.K. Interactions between obstructive sleep apnea and the metabolic syndrome. Curr. Diabetes Rep. 2005, 5, 53–58. [Google Scholar] [CrossRef]
  80. Watanabe, K.; Watanabe, R.; Konii, H.; Shirai, R.; Sato, K.; Matsuyama, T.-a.; Ishibashi-Ueda, H.; Koba, S.; Kobayashi, Y.; Hirano, T. Counteractive effects of omentin-1 against atherogenesis. Cardiovasc. Res. 2016, 110, 118–128. [Google Scholar] [CrossRef] [Green Version]
  81. Yoo, H.J.; Hwang, S.Y.; Hong, H.C.; Choi, H.Y.; Yang, S.J.; Seo, J.A.; Kim, S.G.; Kim, N.H.; Choi, K.M.; Choi, D.S. Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes. Cardiovasc. Diabetol. 2011, 10, 103. [Google Scholar] [CrossRef]
  82. Wang, W.; Pan, Y.; Li, Q.; Wang, L. Orexin: A potential role in the process of obstructive sleep apnea. Peptides 2013, 42, 48–54. [Google Scholar] [CrossRef] [PubMed]
  83. Rilling, F.L.; Reyes, M.; Blanco, E.; Burrows, R.; Peirano, P.; Algarín, C.; Meroño, T.; Gahagan, S. Association of fasting Orexin-A levels with energy intake at breakfast and subsequent snack in Chilean adolescents. Psychoneuroendocrinology 2022, 140, 105718. [Google Scholar] [CrossRef] [PubMed]
Life 13 00245 g001 550
Figure 1. Flowchart of the study selection. * The reasons of exclusion of full-text articles.
Figure 1. Flowchart of the study selection. * The reasons of exclusion of full-text articles.
Life 13 00245 g001
Life 13 00245 g002 550
Figure 2. Forest plot analysis of blood omentin-1 levels in adults with obstructive sleep apnea compared to controls. SD: Standard deviation. CI: Confidence interval.
Figure 2. Forest plot analysis of blood omentin-1 levels in adults with obstructive sleep apnea compared to controls. SD: Standard deviation. CI: Confidence interval.
Life 13 00245 g002
Life 13 00245 g003 550
Figure 3. Forest plot analysis of blood orexin-A levels in adults with obstructive sleep apnea compared to controls. SD: Standard deviation. CI: Confidence interval.
Figure 3. Forest plot analysis of blood orexin-A levels in adults with obstructive sleep apnea compared to controls. SD: Standard deviation. CI: Confidence interval.
Life 13 00245 g003
Life 13 00245 g004 550
Figure 4. The radial (or Galbraith) plot of the blood levels of (A) omentin-1 and (B) orexin-A in adults with obstructive sleep apnea compared to controls. This plot shows the z-statistic on the Y axis and 1/standard error on the X axis. Studies within and outside the limits are interpreted as homogeneous and may be outliers, respectively.
Figure 4. The radial (or Galbraith) plot of the blood levels of (A) omentin-1 and (B) orexin-A in adults with obstructive sleep apnea compared to controls. This plot shows the z-statistic on the Y axis and 1/standard error on the X axis. Studies within and outside the limits are interpreted as homogeneous and may be outliers, respectively.
Life 13 00245 g004
Life 13 00245 g005 550
Figure 5. The trial sequential analyses of the blood levels of (A) omentin-1 and (B) orexin-A in adults with obstructive sleep apnea compared to controls. Each black square fill icon shows a study. X-axis and Y-axis show the number of patients and cumulative Z-score, respectively. Horizontal brown lines: conventional boundaries for benefit (up) or harm (down). Sloping full red lines with black square fill icons: trial sequential monitoring boundaries for benefit (up) or harm (down), and futility boundaries. Full blue line with black square fill icons: Z-curve. Vertical red full line: Required information size boundary.
Figure 5. The trial sequential analyses of the blood levels of (A) omentin-1 and (B) orexin-A in adults with obstructive sleep apnea compared to controls. Each black square fill icon shows a study. X-axis and Y-axis show the number of patients and cumulative Z-score, respectively. Horizontal brown lines: conventional boundaries for benefit (up) or harm (down). Sloping full red lines with black square fill icons: trial sequential monitoring boundaries for benefit (up) or harm (down), and futility boundaries. Full blue line with black square fill icons: Z-curve. Vertical red full line: Required information size boundary.
Life 13 00245 g005
Life 13 00245 g006 550
Figure 6. Funnel plots of the blood levels of (A) omentin-1 and (B) orexin-A in adults with obstructive sleep apnea compared to controls with the trim-fill method. Each white circle shows an included study in the meta-analysis and each black circle shows an unpublished study. The white diamond shows overall effect size as calculated in the meta-analysis, and the black diamond shows the corrected effect size.
Figure 6. Funnel plots of the blood levels of (A) omentin-1 and (B) orexin-A in adults with obstructive sleep apnea compared to controls with the trim-fill method. Each white circle shows an included study in the meta-analysis and each black circle shows an unpublished study. The white diamond shows overall effect size as calculated in the meta-analysis, and the black diamond shows the corrected effect size.
Life 13 00245 g006
Table
Table 1. Characteristics of the studies.
Table 1. Characteristics of the studies.
First Author, Publication YearCountryEthnicityCaseControlSampleMeasured Factor
NumberMean Age, YearsMean BMI, kg/m2Mean AHI, events/hNumberMean Age, YearsMean BMI, kg/m2Mean AHI, events/h
Igarashi, 2003 [57]JapanAsian3045.328.631.82046.526.41.9PlasmaOrexin-A
Busquets, 2004 [42]SpainCaucasian27523154134624<5PlasmaOrexin-A
Liao, 2005 (i) [43]ChinaAsian305330.2≥5204822.11.7PlasmaOrexin-A
Liao, 2005 (ii) [43]ChinaAsian305330.2≥5305130.92.3PlasmaOrexin-A
Yao, 2006 [61]ChinaAsian544734642045323.5PlasmaOrexin-A
Wang, 2013 [41]ChinaAsian19249.226.72414448.727.12SerumOmentin-1
Zirlik, 2013 [64]GermanyCaucasian1058.931.740.41053.626.72.7PlasmaOmentin-1
Kurt, 2014 [40]TurkeyCaucasian4648.130.4≥53542.826.4<5SerumOmentin-1
Strueva, 2015 [59]RussiaCaucasian294139.2≥30103822.4<5PlasmaOrexin-A
Uygur, 2016 [60]TurkeyCaucasian9651.430.827.93150.629.61.9SerumOmentin-1
Zhang, 2018 [62]ChinaAsian3040.728.861.52036.127.61.9PlasmaOmentin-1
Bİçer, 2021 [56]TurkeyCaucasian7544.229.4≥57534.125.9<5PlasmaOmentin-1
Oztürk, 2022 [58]TurkeyCaucasian21046.432.631.66242.230.32.8SerumOrexin-A
Zhu, 2022 [63]ChinaAsian7856.626.925.82855.626.23.4PlasmaOrexin-A
BMI: Body mass index. AHI: Apnea–hypopnea index. Please note that Liao et al. [43] reported two independent studies.
Table
Table 2. The Joanna Briggs Institute (JBI) critical appraisal checklist for case–control studies.
Table 2. The Joanna Briggs Institute (JBI) critical appraisal checklist for case–control studies.
First Author, Publication YearThe Joanna Briggs Institute (JBI) Critical Appraisal ChecklistQuality (Total Quality Score)
Q1Q2Q3Q4Q5Q6Q7Q8Q9Q10
Igarashi, 2003 [57]NoYesYesYesYesNoNoYesYesYesModerate (7)
Busquets, 2004 [42]NoNoYesYesYesYesYesYesYesYesModerate (7)
Liao, 2005 (i) [43]NoNoYesYesYesYesNoYesYesYesModerate (6)
Liao, 2005 (ii) [43]NoNoYesYesYesYesNoYesYesYesModerate (6)
Yao, 2006 [61]NoYesYesYesYesYesNoYesYesYesModerate (7)
Wang, 2013 [41]YesYesYesYesYesYesNoYesYesYesHigh (9)
Zirlik, 2013 [64]YesNoYesYesYesYesYesYesYesYesHigh (9)
Kurt, 2014 [40]YesNoYesYesYesYesYesYesYesYesHigh (9)
Strueva, 2015 [59]UnNoNoYesUnUnUnYesYesYesLow (4)
Uygur, 2016 [60]NoYesYesYesYesYesYesYesYesYesHigh (9)
Zhang, 2018 [62]YesYesYesYesYesYesNoYesYesYesHigh (9)
Bİçer, 2021 [56]YesNoYesYesYesNoNoYesYesYesModerate (7)
Oztürk, 2022 [58]YesNoYesYesYesYesNoYesYesYesModerate (8)
Zhu, 2022 [63]YesYesYesYesYesYesNoYesYesYesHigh (10)
Low: score of 1–4, Moderate: score of 5–7, High: score of 8–10. Un: Unclear.
Table
Table 3. Subgroup analysis of the correlation between blood levels of omentin-1 and several variables.
Table 3. Subgroup analysis of the correlation between blood levels of omentin-1 and several variables.
VariableSubgroup (N)SMD95%CIp-ValueI2, %
Min.Max.
Ethnicity
Caucasian (4)−0.29−1.420.840.6296
Asian (2)−1.95−4.540.640.1498
Sample
Serum (3)−1.66−3.830.510.1399
Plasma (3)−0.08−0.680.520.7970
Sample size
≥100 (3)−1.82−3.850.210.0899
<100 (3)0.13−0.640.910.7479
Mean BMI of aOSA, kg/m2
≥30 (3)−0.33−2.171.510.7397
<30 (3)−1.34−3.520.850.2399
Mean BMI of controls, kg/m2
≥30 (0)-----
<30 (6)−0.84−2.190.520.2398
Mean age of aOSA, year
≥45 (4)−1.07−3.010.880.2898
<45 (2)−0.31−0.790.170.2054
Mean age of controls, year
≥45 (3)−1.57−3.360.230.0997
<45 (3)−0.10−0.580.380.6872
Mean AHI of aOSA, events/h
≥40 (2)0.04−1.341.420.9685
<40 (2)−2.68−3.85−1.52<0.0000194
Quality
Moderate (5)−0.98−2.590.620.2398
High (1)−0.12−0.440.200.46-
SMD: Std. mean difference. CI: Confidence interval. BMI: Body mass index. AHI: Apnea–hypopnea index. Adults with OSA: aOSA.
Table
Table 4. Subgroup analysis of the correlation between blood levels of orexin-A and several variables.
Table 4. Subgroup analysis of the correlation between blood levels of orexin-A and several variables.
VariableSubgroup (N)SMD95%CIp-ValueI2, %
Min.Max.
Ethnicity
Caucasian (3)−1.14−3.581.290.3698
Asian (5)0.30−0.901.510.6296
Sample
Serum (1)0.970.671.26<0.00001-
Plasma (7)−0.39−1.540.760.5196
Sample size
≥100 (2)−0.49−3.362.380.7499
<100 (4)−0.10−1.150.950.8594
Mean BMI of aOSA, kg/m2
≥30 (6)−0.02−0.980.940.9794
<30 (2)−0.67−3.211.870.6098
Mean BMI of controls, kg/m2
≥30 (3)0.890.661.12<0.0000141
<30 (5)−0.882.450.690.2796
Mean age of aOSA, year
≥45 (7)−0.11−1.160.930.8396
<45 (1)−0.85−1.59−0.100.03-
Mean age of controls, year
≥45 (6)−0.32−1.620.990.6496
<45 (2)0.10−1.681.870.9295
Mean AHI of aOSA, events/h
≥40 (2)−1.58−5.652.490.4598
<40 (2)−0.12−1.931.700.9098
Quality
Moderate (6)0.25−0.591.080.5693
High (1)−1.96−2.74−1.45<0.00001-
Low (1)−0.85−1.59−0.100.03-
SMD: Std. mean difference. CI: Confidence interval. BMI: Body mass index. AHI: Apnea–hypopnea index. Adults with OSA: aOSA.
Table
Table 5. Meta-regression analysis (mixed-effect model) of the correlation between blood levels of omentin-1 and orexin-A and several variables in the case–control studies in the meta-analysis.
Table 5. Meta-regression analysis (mixed-effect model) of the correlation between blood levels of omentin-1 and orexin-A and several variables in the case–control studies in the meta-analysis.
Omentin-1
VariablePoint EstimateStandard ErrorLower LimitUpper LimitZ-Valuep-Value
Publication year0.083980.24376−0.393790.561750.344500.73047
Sample size−0.011560.00406−0.01952−0.00359−2.844450.00445
Mean BMI of aOSA0.621140.33477−0.034991.277271.855450.06353
Mean BMI of controls−0.629300.57486−1.756000.49740−1.094710.27364
Mean age of aOSA0.031040.12756−0.218970.281060.243350.80773
Mean age of controls−0.049580.08698−0.220060.12090−0.0570010.56867
Mean AHI of aOSA0.065540.04650−0.025600.156681.409400.15872
Quality score−0.429840.99973−2.389271.52959−0.429960.66722
Orexin-A
VariablePoint estimateStandard errorLower limitUpper limitZ-valuep-value
Publication year−0.028530.07419−0.173930.11687−0.384570.70056
Sample size0.005590.00772−0.009540.020720.724320.46887
Mean BMI of aOSA0.018320.14761−0.270990.307630.124110.90123
Mean BMI of controls0.177260.13499−0.087310.441831.313140.18914
Mean age of aOSA−0.077710.10418−0.281900.12647−0.745950.45570
Mean age of controls−0.036280.10193−0.236070.16351−0.355890.72192
Mean AHI of aOSA−0.329460.60582−1516850.85793−0.543820.58657
Quality score−0.245020.31513−0.822670.37262−0.777530.43685
BMI: Body mass index. AHI: Apnea–hypopnea index. Bold number means statistically significant (p < 0.05). Adults with OSA: aOSA.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Mohammadi, I.; Sadeghi, M.; Tajmiri, G.; Brühl, A.B.; Sadeghi Bahmani, L.; Brand, S. Evaluation of Blood Levels of Omentin-1 and Orexin-A in Adults with Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis. Life 2023, 13, 245. https://doi.org/10.3390/life13010245

AMA Style

Mohammadi I, Sadeghi M, Tajmiri G, Brühl AB, Sadeghi Bahmani L, Brand S. Evaluation of Blood Levels of Omentin-1 and Orexin-A in Adults with Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis. Life. 2023; 13(1):245. https://doi.org/10.3390/life13010245

Chicago/Turabian Style

Mohammadi, Iman, Masoud Sadeghi, Golnaz Tajmiri, Annette Beatrix Brühl, Laleh Sadeghi Bahmani, and Serge Brand. 2023. "Evaluation of Blood Levels of Omentin-1 and Orexin-A in Adults with Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis" Life 13, no. 1: 245. https://doi.org/10.3390/life13010245

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop